Etentamig (ABBV-383)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 440 patients (estimated)
- Sponsors
- AbbVie
- Tags
- Bispecific Antibody, CD3, B-Cell Maturation Antigen (BCMA), Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2149
- NCT Identifier
- NCT06892522
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.